Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Other Gross PP&E Adjustments (2022 - 2025)

Corvus Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 4 years, most recently at $1.7 million for Q3 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $1.7 million for Q3 2025, down 59.88% from a year ago — trailing twelve months through Sep 2025 was $1.7 million (down 59.88% YoY), and the annual figure for FY2024 was -$2.3 million, down 9.48%.
  • Other Gross PP&E Adjustments for Q3 2025 was $1.7 million at Corvus Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for CRVS hit a ceiling of $4.2 million in Q3 2024 and a floor of -$2.8 million in Q4 2022.
  • Median Other Gross PP&E Adjustments over the past 4 years was $2.0 million (2022), compared with a mean of $1.6 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 65.25% in 2023 and later tumbled 66.29% in 2025.
  • Corvus Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.8 million in 2022, then grew by 25.17% to -$2.1 million in 2023, then dropped by 9.48% to -$2.3 million in 2024, then surged by 173.46% to $1.7 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $1.7 million (Q3 2025), $1.5 million (Q2 2025), and $1.2 million (Q1 2025) per Business Quant data.